Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy

S Mansouri, P Lavigne, K Corsi, M Benderdour… - European journal of …, 2004 - Elsevier
Currently, the major drawback of gene therapy is the gene transfection rate. The two main
types of vectors that are used in gene therapy are based on viral or non-viral gene delivery …
被引用次数：741 相关文章

Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy

S Mansouri, P Lavigne, K Corsi… - … : official journal of …, 2004 - pubmed.ncbi.nlm.nih.gov
Currently, the major drawback of gene therapy is the gene transfection rate. The two main
types of vectors that are used in gene therapy are based on viral or non-viral gene delivery …
[PDF] researchgate.net

[PDF][PDF] Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy

S Mansouri, P Lavigne, K Corsi… - European Journal of …, 2004 - researchgate.net
Currently, the major drawback of gene therapy is the gene transfection rate. The two main
types of vectors that are used in gene therapy are based on viral or non-viral gene delivery …

[引用][C] Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy

S MANSOURI - Eur J Pharm Biopharm, 2004 - cir.nii.ac.jp
Chitosan-DNA nanoparticles as non-viral vectors in gene therapy : strategies to improve
transfection efficacy | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
[PDF] academia.edu

[PDF][PDF] Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy

S Mansouri, P Lavigne, K Corsi… - European Journal of …, 2004 - academia.edu
Currently, the major drawback of gene therapy is the gene transfection rate. The two main
types of vectors that are used in gene therapy are based on viral or non-viral gene delivery …

Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy.

S Mansouri, P Lavigne, K Corsi… - European Journal of …, 2004 - europepmc.org
Currently, the major drawback of gene therapy is the gene transfection rate. The two main
types of vectors that are used in gene therapy are based on viral or non-viral gene delivery …

Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy

S Mansouri, P Lavigne, K Corsi, M Benderdour… - European Journal of …, 2004 - infona.pl
Currently, the major drawback of gene therapy is the gene transfection rate. The two main
types of vectors that are used in gene therapy are based on viral or non-viral gene delivery …

Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy

S MANSOURI, P LAVIGNE, K CORSI… - European journal of …, 2004 - cat.inist.fr
Résumé/Abstract Currently, the major drawback of gene therapy is the gene transfection
rate. The two main types of vectors that are used in gene therapy are based on viral or non …
[PDF] academia.edu

[PDF][PDF] Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy

S Mansouri, P Lavigne, K Corsi… - European Journal of …, 2004 - academia.edu
Currently, the major drawback of gene therapy is the gene transfection rate. The two main
types of vectors that are used in gene therapy are based on viral or non-viral gene delivery …

[引用][C] Chitosan/DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy

S MANSOURI - Eur. J. Pharm. Biopharm., 2004 - cir.nii.ac.jp
Chitosan/DNA nanoparticles as non-viral vectors in gene therapy : strategies to improve
transfection efficacy | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …